Home » Newsletters » BioWorld Science

BioWorld Science

March 11, 2019

View Archived Issues

AQAMAN: Heroic inhibitor restrains polyQ aggregation

Gilead presents first data for anti-HIV antibody GS-9722

Beijing Xuanyi Pharmasciences patents CDK4 and CDK6 inhibitors

Istituto Europeo di Oncologia discloses new KDM1A inhibitors

STING innate immune protein induces autophagy

Innate immune signaling complexes are multifunctional, programmable

Agios Pharmaceuticals synthesizes PKM activators

PROLONG study of Makena does not meet coprimary endpoints

GlaxoSmithKline identifies new compounds for tuberculosis

Saint Louis University discloses ESRRG inverse agonists

Interim phase I data reported for GS-6207

GlaxoSmithKline's GSK-2838232 shows activity in phase IIa study in patients with HIV

Discovery of new TRPV4 agonist as regulators of chondrogenic differentiation

Saniona initiates phase IIa study of Tesomet for hypothalamic obesity

FDA grants accelerated approval to Tecentriq plus chemotherapy in PD-L1-positive metastatic TNBC

Pharmacokinetic data on VRC-01 LS in HIV-exposed newborns reported

Topline results from first-in-human study of TLC-590 for postsurgical pain

Dicerna enrolling in phase II study of DCR-PHXC for primary hyperoxaluria

MGB Biopharma studies MGB-BP-3 for C. difficile-associated diarrhea in new phase IIa trial

UCL initiates phase I/II study of MSCTRAIL in metastatic NSCLC

ProQR initiates first-in-human study of QR-421a for Usher's syndrome type 2

FDA clears Rubius' IND application for phase Ib trial of RTX-134 for PKU

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...